| Similar Articles |
|---|
 |
The Motley Fool
March 3, 2011
Brian D. Pacampara |
Amylin Pharmaceuticals Shares Plunged: What You Need to Know Shares of Amylin Pharmaceuticals plummeted more than 20% Thursday after its type 2 diabetes drug Bydureon failed to meet primary endpoints in a 26-week study.   |
The Motley Fool
November 8, 2011
Tim Beyers |
Amylin Pharmaceuticals Shares Plummeted: What You Need to Know Is this meaningful, or just another movement for Amylin Pharmaceuticals? |
The Motley Fool
October 20, 2011
Travis Hoium |
Amylin Pharmaceuticals Shares Jumped: What You Need to Know Shares of Amylin Pharmaceuticals jumped 11% today after the company released great earnings and pipeline news. |
The Motley Fool
January 27, 2011
Travis Hoium |
Buckeye Technologies Shares Popped Again: What You Need to Know A day after popping on great earnings news, shares of Buckeye Technologies gained 10% today after an analyst upgrade. |
The Motley Fool
March 3, 2011
Brian Orelli |
Amylin Comes Up Snake Eyes Amylin Pharmaceuticals and partners Eli Lilly and Alkermes announced results of their head-to-head clinical trial comparing Bydureon with Novo Nordisk's diabetes drug Victoza. |
The Motley Fool
July 22, 2010
Brian Orelli |
It's All About the Future for Amylin Its second quarter stank, but there's a lot up ahead. |
The Motley Fool
November 9, 2011
Brian Orelli |
Byetta Breakup! Buying Opportunity? We all saw this coming. Amylin Pharmaceuticals and Eli Lilly decided staying together for the kids just wasn't worth it |
The Motley Fool
June 16, 2010
Brian Orelli |
A Drop on Bad News, but It Was a Long Shot Anyway Bydureon, Amylin Pharmaceuticals and Eli Lilly's once-weekly version of their twice-daily Byetta, has been beating up other diabetes drugs in a series of head-to-head clinical trials but it will have a tough time going after the monotherapy market. |
The Motley Fool
January 27, 2011
Brian Orelli |
Amylin Timeline Shortened -- Maybe Revenue down 6% year over year. Prescriptions of the company's top-selling drug, Byetta, down 5.9% quarter over quarter. Amylin Pharmaceuticals' fourth quarter wasn't pretty. |
The Motley Fool
November 24, 2006
Brian Lawler |
Amylin Gets Past the Formalities Following a formal approval from the EU for Byetta, Amylin can get down to business. Investors, take note. |
The Motley Fool
April 20, 2010
Brian Orelli |
Drug Sales Down! Should We Celebrate? Amylin won't have completed results for a trial comparing Bydureon to Victoza until next year. But until that data is in, it might not be as easy to get the patients back as Amylin is making it out to be. |
The Motley Fool
October 20, 2010
Brian Orelli |
There Are No Safe Biotech Investments Amylin Pharmaceuticals and its partners, Eli Lilly and Alkermes, announced yesterday evening that the Food and Drug Administration had asked for more data before approving its once-weekly diabetes drug Bydureon. |
The Motley Fool
May 16, 2011
Brian Orelli |
Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly. |
The Motley Fool
March 15, 2010
Brian Orelli |
FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it. |
The Motley Fool
July 22, 2008
Brian Orelli |
Anemic Amylin's Signs of Recovery Sales of Amylin Pharmaceuticals' diabetes drug Byetta have slowed over the last few quarters, but the company seems to be turning things around. |
The Motley Fool
October 21, 2011
Brian Orelli |
Full of News, but Worth a 15% Gain? Amylin serves up an appetizer. |
The Motley Fool
April 15, 2011
Brian Orelli |
Fewer Needle Pricks for the Europeans Amylin's once-weekly diabetes drug Bydureon gets a positive recommendation in Europe. |
The Motley Fool
July 8, 2011
Luke Timmerman |
Amylin, Alkermes Once-Weekly Diabetes Drug Passes Heart Trial What does this mean for the drug companies? |
The Motley Fool
April 15, 2011
Luke Timmerman |
Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug Will this drug be approved in Europe? |
The Motley Fool
June 11, 2008
Brian Orelli |
Amylin's Down and Up on Diabetes Investors may be over-reacting to news both good and bad from Amylin Pharmaceuticals. |
Chemistry World
July 3, 2012
Andrew Turley |
BMS and AstraZeneca buy Amylin for $7bn Pharma giants Bristol-Myers Squibb and AstraZeneca have teamed up to buy US biotech Amylin for $7 billion, further strengthening their position in the burgeoning market for diabetes drugs. |
The Motley Fool
August 19, 2008
Brian Orelli |
Too Much Punishment for Amylin Several more pancreatitis cases cause Amylin Pharmaceuticals' investors to panic. |
The Motley Fool
November 8, 2011
David Williamson |
Biotech Pops, Drops, and Break-Ups Highlighting the day's health-care stories critical to investors. |
The Motley Fool
April 22, 2008
Brian Orelli |
Amylin Treads Water One-drug wonders like Amylin Pharmaceuticals can't get away with stagnant growth. |
The Motley Fool
October 19, 2006
Brian Lawler |
Amylin's One-Drug Wonder Unfortunately, with research and development costs growing to $54 million from $33 million last year, Amylin is still a few quarters away from profitability. Diabetes drug Byetta is set to boost Amylin's sales. Investors, take note. |
The Motley Fool
August 27, 2008
Brian Orelli |
Amylin Answers, Investors Panic Amylin Pharmaceuticals' conference call about side effects of its diabetes treatment, Byetta, doesn't have the desired effect. |
The Motley Fool
September 22, 2010
Brian Orelli |
Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown. |
The Motley Fool
May 19, 2008
Brian Orelli |
What Will Icahn Do With Amylin? Carl Icahn recently took an initial position now worth around $200 million in Amylin Pharmaceuticals, and stockholders must be wondering about his motivation for the purchase. |
The Motley Fool
January 31, 2007
Brian Lawler |
No Sickness for Amylin Sales of the drugmaker's type-2 diabetes drugs showed solid growth. Investors, take note. |
The Motley Fool
August 31, 2011
Brian Orelli |
3 Biotechs Ready to Move Here are three biotechs with upcoming events that could drive their value higher: Exelixis... BioSante Pharmaceuticals... Amylin Pharmaceuticals... |
The Motley Fool
November 26, 2010
Brian Orelli |
Black Friday Biotech Bargains Drugmakers on sale. |
The Motley Fool
July 8, 2011
Brian Orelli |
Let's Just Hope For No More FDA Surprises Despite the government's worries, Bydureon doesn't cause heart issues. |
The Motley Fool
August 20, 2010
Brian Orelli |
This Billionaire Likes Biotech. Should You? It depends on how much you trust management. |
The Motley Fool
March 17, 2011
Brian Orelli |
Taking a Bite Out of Amylin's Obesity Drug Potential Amylin Pharmaceuticals and Takeda announce they were putting a hold on the development of their obesity drug combination pramlintide/metreleptin due to safety issues. |
The Motley Fool
November 24, 2010
Brian Orelli |
Profit From the United States of Diabetes Half the country could have an early form by 2020. |
The Motley Fool
November 3, 2009
Brian Orelli |
Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend. |
The Motley Fool
November 16, 2007
Brian Orelli |
Weighing In on Amylin's Drug Combination Phase 2 results are good for Amylin Pharmaceuticals trial of a new weight-loss treatment, but it's the subsequent phase 3 trial that actually counts. |
The Motley Fool
January 30, 2009
Brian Orelli |
Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%. |
The Motley Fool
January 29, 2008
Brian Orelli |
No Weight Loss at Amylin Bulging costs related to its diabetes drug Byetta keep the drugmaker from showing a profit this quarter. |
InsideFlyer
May 2009 |
Upgrades with Privilege Club Qatar Airways has created more upgrade opportunities for Privilege Club members. |
The Motley Fool
October 22, 2008
Brian Orelli |
Why Amylin Skipped Some Byetta Numbers Usually the company presents the individual sales numbers for its two diabetes drugs from the year-ago quarter for investors to compare. But this time they were conspicuously absent. |
The Motley Fool
January 28, 2010
Brian Orelli |
The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends. |
The Motley Fool
December 12, 2008
Brian Orelli |
Amylin Gets Some FDA Love Amylin's once-weekly diabetes drug Byetta gets a green light from the FDA. |
The Motley Fool
June 24, 2010
Luke Timmerman |
Amylin Cuts 60 Jobs The pharmaceutical company says research is still a priority. |
The Motley Fool
April 17, 2009
Brian Orelli |
Cost-Cutting? Check. Increased Sales? Hmm ... Amylin has half the equation. Now it needs the other half. |
The Motley Fool
December 9, 2008
Brian Orelli |
FDA Dashes Amylin Investors' Hopes Shareholders are still waiting to hear how much longer it'll be before Amylin and Eli Lilly can submit the marketing application for the once-weekly version of diabetes drug Byetta. |
The Motley Fool
March 27, 2009
Brian Orelli |
The Skinny on a Triple-Decker Update Amylin's public relations department might need to go on a diet. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
BusinessWeek
January 9, 2006 |
Bio: Ginger L. Graham Throughout her life, Amylin Pharmaceuticals CEO Ginger Graham has demonstrated a theatrical flair and a persistence in the face of tough challenges. |
The Motley Fool
October 2, 2007
Brian Orelli |
Amylin's Bittersweet FDA News Diabetes drug moves ahead, but not as much as the company wanted. If the FDA rejection was due to safety issues, that wouldn't bode well for Amylin's plans to develop the active ingredient in SYMLIN as a weight-loss drug. Investors, take note. |
